Recalcitrant Lichen Planopilaris Treated with Upadacitinib: A Case Series

    June 2024 in “ International Journal of Dermatology ”
    Miguel Antonio Lasheras‐Pérez, Rodolfo David Palacios‐Diaz, Conrad Pujol‐Marco, Begoña Escutia‐Muñoz, Rafael Botella‐Estrada
    Image
    Studysummary This article in the International Journal of Dermatology reports on a case series where the drug upadacitinib was used to treat patients with recalcitrant lichen planopilaris, but no abstract or detailed results are provided to assess its efficacy or safety fully.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    This case series explores the treatment of recalcitrant lichen planopilaris (LPP) with upadacitinib, a Janus kinase (JAK) inhibitor. The study, conducted by the Department of Dermatology at La Fe University and Polytechnic Hospital in Valencia, Spain, presents evidence that upadacitinib may be an effective treatment option for patients with LPP who have not responded to other therapies. The authors report positive outcomes in the cases treated, suggesting that JAK inhibitors could play a significant role in managing this challenging condition. No conflicts of interest or funding sources were reported.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results